Starpharma will utilise its DEP® technology to develop a range of DEP® nanoparticle formulations for Chase Sun.
The Initial project is for the development of DEP® conjugates for an anti-infective drug, with an ability to add additional programs in other therapeutic areas.
Starpharma Holdings Limited (ASX: SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.